Low Intensity Focused Ultrasound for Binge Eating Disorder

Last updated: December 17, 2024
Sponsor: Ali Rezai
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bulimia

Binge Eating Disorder

Treatment

LIFU Neuromodulation

Clinical Study ID

NCT06485687
RNI_NMD_BED01
  • Ages 22-65
  • All Genders

Study Summary

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with Binge Eating Disorder (BED)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Males and non-pregnant females, 22 - 65 years of age.

  • Participant meets DSM-5 criteria for moderate to extreme BED.

  • Weight ≤450lb to accommodate in MRI.

  • Shoulder width of ≤65 inches to accommodate in MRI.

  • The neuromodulation targets are visible on MRI for target selection.

  • Participant is able and willing to give informed consent.

Exclusion

Exclusion Criteria:

  • Unable to undergo MR-imaging because of implanted pacemakers, medication pumps,aneurysm clips, metallic prostheses (including metal pins and rods, heart valves orcochlear implants), shrapnel fragments, permanent make-up or small metal fragmentsin the eye that welders and other metal workers may have, or if candidates areuncomfortable in small spaces (have claustrophobia).

  • Participants with more than 30% of the skull area traversed by the sonicationpathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp,or implanted objects in the skull or the brain.

  • Participants with known untreated or unstable cardiac status or hypertension

  • Evidence of substance (alcohol or other drug) use disorder during the previous 12months (assessed via SCID-5).

  • Past or present diagnosis of schizophrenia, psychotic disorder or bipolar disorder (assessed via SCID-5)

  • Participant who is currently participating in another clinical investigation with anactive treatment arm.

  • Use of any medications that, in the opinion of the Investigator, may put theparticipant at higher risk for AEs, or impair the participant's ability to performcomplete study procedures.

  • Participant is considered to be a poor surgical or study candidate, which mayinclude, but is not limited to the following: any medical, social, or psychologicalproblem that could complicate the required procedures and evaluations of the studyin the judgment of the investigator.

  • Participant is pregnant/lactating or planning to be pregnant.

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: LIFU Neuromodulation
Phase:
Study Start date:
October 31, 2024
Estimated Completion Date:
December 31, 2027

Study Description

The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for BED

Connect with a study center

  • West Virginia University: Rockefeller Neuroscience Institute

    Morgantown, West Virginia 26506
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.